36 Results for "

malignant human cells

" in MedChemExpress (MCE) Product Catalog:
Products (36)

36 Results for "malignant human cells" in MCE Product Catalog:

31
31 Publications Verification
Cat. No.: HY-19824
CAS No.: 18550-98-6
Target:  

Autophagy

Research Areas:  

Cancer

3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC50s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD + and NADH. 3PO can be used for the research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145925B
CAS No.: 2704617-96-7
Purity:  98.10%
Research Areas:  

Cancer

CFT8634 is an orally active BRD9 PROTAC degrader with a DC50 of 0.003 μM (HEK293T.166). CFT8634 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, triggering CRBN-catalyzed BRD9 polyubiquitination and 26S proteasome-mediated degradation. CFT8634 induces sustained tumor regression and inhibits tumor growth in mouse models. CFT8634 can be used in research related to synovial sarcoma, SMARCB-1-deficient cancers, acute myeloid leukemia, malignant rhabdoid tumors, and multiple myeloma .
loading...
    loading...
Cat. No.: HY-B0766
CAS No.: 118159-48-1
Synonyms: SY801
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-N4114
CAS No.: 138-55-6
Picrocrocin, an apocarotenoid found in Saffron. Picrocrocin shows anticancer effect. Picrocrocin exhibits growth inhibitory effects against SKMEL-2 human malignant melanoma cells .
loading...
    loading...
Cat. No.: HY-P991155
CAS No.: 2988886-91-3
Synonyms: JNJ-79635322; JNJ-5322

Target:  

CD3 TNF Receptor

Research Areas:  

Cancer

Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
loading...
    loading...
Cat. No.: HY-13631J
CAS No.: 2938875-39-7
Purity:  99.94%
Synonyms: (1R,9R)-DX8951f
Research Areas:  

Cancer

(1R,9R)-Exatecan mesylate ((1R,9R)-DX8951f) is a non-prodrug camptothecin derivative and a potent topoisomerase I inhibitor (IC50=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1R,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1R,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1R,9R)-Exatecan mesylate is widely used in preclinical studies of multiple cancers including pancreatic cancer, lung cancer, breast cancer, and leukemia . The low-activity isomer of (1R,9R)-Exatecan mesylate is (1S,9R)-Exatecan mesylate (HY-13631I).
loading...
    loading...
Cat. No.: HY-P99781
CAS No.: 1610761-46-0
Synonyms: MLN-1202

Target:  

CCR

Research Areas:  

Inflammation/Immunology Cancer

Plozalizumab (MLN-1202) is a humanized anti-CCR2 IgG1 monoclonal antibody. Plozalizumab blocks the recruitment of myeloid cells to the tumor microenvironment by inhibiting the CCL2/CCR2 axis. In addition, Plozalizumab also ameliorates synovial inflammation in rheumatoid arthritis. Plozalizumab can be used in the research of malignant melanoma and bone metastasis-related cancers. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-13631I
CAS No.: 2938875-54-6
Purity:  98.48%
Synonyms: (1S,9R)-DX8951f
Research Areas:  

Cancer

(1S,9R)-Exatecan mesylate ((1S,9R)-DX8951f) is a non-prodrug camptothecin derivative and a topoisomerase I inhibitor (IC50=0.975 μg/mL in mice and 0.82 μg/mL in humans). (1S,9R)-Exatecan mesylate blocks enzyme activity and induces apoptosis by stabilizing the enzyme-DNA cleavable complex. (1S,9R)-Exatecan mesylate not only effectively inhibits the proliferation of various malignant tumor cells and tumor growth, but also circumvents P-glycoprotein-mediated multidrug resistance. (1S,9R)-Exatecan mesylate is widely used in preclinical studies of various cancers such as pancreatic cancer, lung cancer, breast cancer, and leukemia .
The chiral isomer of (1S,9R)-Exatecan mesylate is (1R,9R)-Exatecan mesylate (HY-13631J).
loading...
    loading...
Cat. No.: HY-148819A
Purity:  98.46%
Research Areas:  

Cancer

NH2-bicyclopentane-7-MAD-MDCPT hydrochloride (Formula I) is a topoisomerase I (TOP1) inhibitor. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is applicable to the synthesis of the ADC ABBV-969. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is used in research on lung adenocarcinoma and melanoma .
loading...
    loading...
Cat. No.: HY-P99641
CAS No.: 1808081-43-7

Research Areas:  

Cancer

Gilvetmab is a canine-derived anti-cPD-1 monoclonal antibody, as well as an immune activator/antitumor agent. Gilvetmab binds to canine PD-1, blocks the interaction of PD-1/PD-L1/L2, prevents immunosuppression, reactivates antitumor responses, induces tumor regression or disease stabilization, and may also trigger pseudoprogression. Gilvetmab can be used in research related to malignant melanoma and mast cell tumors .
loading...
    loading...
Cat. No.: HY-P99806
CAS No.: 499212-74-7
Synonyms: ACA-11; CLN-IgG; CLNH-11

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research .
loading...
    loading...
Cat. No.: HY-143411
CAS No.: 2487526-28-1
Research Areas:  

Cancer

GEM144 is a potent and orally active DNA polymerase α (POLA1) and HDAC 11 dual inhibitor. GEM144 induces acetylation of p53, activation of p21, G1/S cell cycle arrest, and apoptosis. GEM144 has significant antitumor activity in human orthotopic malignant pleural mesothelioma xenografts .
loading...
    loading...
Cat. No.: HY-P991225

Target:  

Fc Receptor (FcR) CD20

Research Areas:  

Inflammation/Immunology Cancer

BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
loading...
    loading...
Cat. No.: HY-P991525
CAS No.: 2923542-55-4

Target:  

Fc Receptor (FcR)

Research Areas:  

Cancer

2141-V11 is an Fc-engineered agonistic antibody against human CD40 with selectively enhanced binding affinity for human FcγRIIB. 2141-V11 drives CD40 multimerization and agonistic signal transduction, activates dendritic cells, promotes antigen cross-presentation and CD8 + T cell priming, induces tertiary lymphoid structure formation, increases leukocyte infiltration, and mediates local and abscopal anti-tumor effects, systemic immune activation and immune memory. 2141-V11 exhibits extremely low systemic toxicity upon intratumoral or intravesical administration, with no dose-limiting toxicity observed at the tested intratumoral doses, whereas high-dose systemic administration induces thrombocytopenia and elevated transaminases. 2141-V11 can be used in research related to breast cancer, melanoma, BCG-unresponsive non-muscle invasive bladder cancer, and recurrent malignant glioma .
loading...
    loading...
Cat. No.: HY-N4114R
CAS No.: 138-55-6
Picrocrocin (Standard) is the analytical standard of Picrocrocin. This product is intended for research and analytical applications. Picrocrocin, an apocarotenoid found in Saffron. Picrocrocin shows anticancer effect. Picrocrocin exhibits growth inhibitory effects against SKMEL-2 human malignant melanoma cells .
loading...
    loading...
Cat. No.: HY-177275
CAS No.: 932401-20-2
Target:  

c-Kit

Research Areas:  

Cancer

c-Kit Receptor modulator-1 (Compound #22) is a c-Kit Receptor modulator. c-Kit Receptor modulator-1 can be used for malignant cancers such as canine mastocytoma, human gastrointestinal stromal tumor and small cell lung cancer research .
loading...
    loading...
Cat. No.: HY-174336
Target:  

Survivin Apoptosis

Research Areas:  

Cancer

Survivin-IN-1 (Compound II₃) is a potent Survivin (a member of the Inhibitor of Apoptosis Protein family) inhibitor with an IC50 value of 8.1 μM against human lung cancer A549 cells and 9.0 μM against breast cancer MCF-7 cells. Survivin-IN-1 reduces Survivin protein levels and induces tumor cell apoptosis. Survivin-IN-1 is promising for research of malignant tumors such as lung cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-P991738

Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

LM-299 is a bispecific antibody targeting PD-1 and VEGF with anti-tumor activity. The dual binding activity of LM-299 is achieved through the effective binding of its Fab-terminal anti-VEGF-A antibody to human VEGF-A, as well as the blocking effect of its Fc-terminal anti-PD-1 antibody on the PD-1/PD-L1 pathway. LM-299 binds to and modulates PD-1 and VEGF. LM-299 can be used in studies related to advanced malignant tumors, advanced solid tumors, and advanced non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-12814A
CAS No.: 1640282-30-9
Research Areas:  

Cancer

TH588 hydrochloride is a highly selective human MTH1 inhibitor (IC50=5 nM) with additional microtubule-targeting properties. TH588 hydrochloride interferes with mitotic progression, induces genomic 8-oxodG formation, DNA damage and cell cycle arrest, and exhibits significant cytotoxicity. Combined with phenethyl isothiocyanate, TH588 hydrochloride enhances ROS-mediated effects and effectively inhibits the growth of visceral metastases of malignant melanoma in mice. TH588 hydrochloride is widely applicable to research related to cancers, pancreatic cancer, leukemia, lymphoma, malignant melanoma and lung cancer .
loading...
    loading...
Cat. No.: HY-147706
CAS No.: 2568148-31-0
Target:  

Others

Research Areas:  

Cancer

Ar524 has higher inhibitory activity than the known transgenic inhibitor kifunensine. At the same time, ar524 inhibited low concentration (10 μ M) Spheroid formation of human malignant cells.
loading...
    loading...